37th week of 2010 patent applcation highlights part 39 |
Patent application number | Title | Published |
20100233072 | Electrically-Reduced Lithium Tantalate Compositions - According to some embodiments, a pre-poled, single-domain body of a ferroelectric crystalline material such as lithium tantalate or lithium niobate is electrically reduced by applying a voltage across the body in a non-oxidizing environment while the body is heated to a process temperature below its Curie temperature. The voltage generates an electric field along the polar axis of the body. Electrodes may be formed on the body surface by applying an acetate-based silver paint. Exemplary methods allow achieving lithium tantalate electrical conductivity values of 10 | 2010-09-16 |
20100233073 | Manufacturing Method of Highly Pure Alpha-LiAlO2 - The present invention relates to a method for preparing high-purity alpha-lithium aluminate (α-LiAlO | 2010-09-16 |
20100233074 | SYNTHETIC METHOD OF TRANSITION METAL OXIDE NANO-PARTICLES - Provided is a method for preparing transition metal oxide nanoparticles from a transition metal as a reactant. The method includes dissolving the transition metal into aqueous hydrogen peroxide to provide peroxi-metallate solution, and then adding a reactive solution containing an alcohol, water and an acid thereto to perform hydrothermal reaction. | 2010-09-16 |
20100233075 | PROCESS FOR PREPARING TI-DOPED HYDRIDES - The present invention provides a process for the preparation of Ti-doped alkali metal and/or alkaline-earth metal aluminium hydride, comprising intimately mixing: an alkali metal and/or alkaline-earth metal aluminium hydride, or at least one alkali metal hydride and/or alkaline-earth metal hydride, metallic aluminium and H | 2010-09-16 |
20100233076 | Hydrogen Storage Materials - According to at least one aspect of the present invention, a hydrogen storage material is provided. In at least one embodiment, the material comprises a borohydride compound of the formula M(BH | 2010-09-16 |
20100233077 | Solid Hydrogen Fuel and Method of Manufacturing and Using the Same - A solid hydrogen fuel is formed into a solid pressure-formed block. The method of manufacturing the solid hydrogen fuel includes following steps. First, at least a hydride powder and at least a hydrogen releasing catalyst powder are mixed well. Next, the mixed powder is bonded into a block by pressure. When in use, the solid hydrogen fuel is mixed with water to produce hydrogen. The hydride powder and water bring about a hydrogen releasing reaction. The hydride releasing catalyst powder is used for catalyzing the hydrogen releasing reaction to produce hydrogen. The solid hydride has higher hydrogen production and can release hydrogen completely. | 2010-09-16 |
20100233078 | Microorganisms for imaging and/or treatment of tumors - Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in diagnostic methods, such detection and imaging of tumors. The viruses also can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. | 2010-09-16 |
20100233079 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 2010-09-16 |
20100233080 | Antigen Binding Molecules that Bind EGFR, Vectors Encoding Same, and Uses Thereof - The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function. | 2010-09-16 |
20100233081 | METHODS FOR ADMINISTRATION OF RADIOTHERAPEUTIC AGENTS - A method is provided for treatment of disorders involving hyperproliferative cells, such as malignancies, advanced stage solid tumors like glioblastoma multiforme, and non-malignant hyperproliferative pathological conditions such as adult macular degeneration. A short range, unselective cell killing radiotherapeutic substance is administered, optionally in a spatially defined volume of tissue, optionally in combination with a mitogenic agent that stimulates or induces DNA biosynthesis. In this way, the percentage of hyperproliferative that are susceptible to killing by the radiotherapeutic agent is increased. Cancer stem cells can be induced to enter S phase with the mitogenic agent, then killed with the radiotherapeutic agent. Thus, not only does the combination effectively kill the transit amplifying cell population, the most rapidly replicating type of cell in a tumor, but it also effectively kills the tumor stem cells, which give rise to the transit amplifying cells, for a longer lasting anticancer effect. | 2010-09-16 |
20100233082 | 68GA-Labeled Peptide-Based Radiopharmaceuticals - The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors. | 2010-09-16 |
20100233083 | MICROPARTICLES COMPRISING A CROSSLINKED POLYMER - The present invention relates to a microparticle comprising a crosslinked polymer, which polymer is composed of a crosslinkable compound represented by the formula (I) wherein—X is a residue of a multifunctional radically polymerisable compound (having at least a functionality equal to n);—each Y independently is optionally present, and—if present—each Y independently represents a moiety selected from the group of O, S and NR | 2010-09-16 |
20100233084 | Method for Delivery Across the Blood Brain Barrier - The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The compositions and methods are useful for delivering agents across the blood-brain barrier. The present invention also provides methods of using the compositions provided by the present invention to deliver agents, for example therapeutic agents for the treatment of neurologically related disorders. | 2010-09-16 |
20100233085 | IONIC COMPLEX NANOPARTICLES FOR DETECTING HEPARANASE ACTIVITIES AND METHOD FOR PREPARING THE SAME - Disclosed are Ionic complex nanoparticles for detecting heparanase activities and a method for preparing the same. More specifically, disclosed are Ionic complex nanoparticles for detecting heparanase activities, wherein negative-ion substrate polymers specifically degraded by heparanase and positive-ion biocompatible polymers ionically bind to each other, and fluorophores or quenchers bind to each of the polymers. The ionic complex nanoparticles for detecting heparanase activities may be applied to a method for screening novel drugs such as inhibitors that prevent over-expression of heparanase. Various cells and tissues where over-expression of heparanase occurs may be non-invasively imaged in cancer cells, cancer tissues, and tissues of various inflammatory diseases. Accordingly, the ionic complex nanoparticles for detecting heparanase activities may be effectively used to early diagnose various diseases and incurable diseases including autoimmune diseases such as cancers, osteoarthritis, rheumatoid arthritis, and dementia. | 2010-09-16 |
20100233086 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS - This invention relates to novel compounds suitable for labelling or already labelled by | 2010-09-16 |
20100233087 | CYP1B1 NUCLEIC ACIDS AND METHODS OF USE - The present invention provides nucleic acids containing transcriptional units that encode CYP1B1 polypeptides or portions thereof, wherein the transcriptional units lack sequences found in the untranslated region (UTR) of naturally occurring forms of the CYP1B1 transcript. The nucleic acids of the invention lack translational repressor elements and thus provide for a system of enhanced translation of the CYP1B1 polypeptide or portions thereof. Also disclosed are methods of administering nucleic acids to a mammal and use in the treatment of proliferative disorders or cancer. | 2010-09-16 |
20100233088 | METHOD OF IDENTIFYING STRATEGIES FOR TREATMENT OR PREVENTION OF VENTRICULAR FIBRILATION AND VENTRICULAR TACHYCARDIA - The present invention relates to evaluating the effect of physiological conditions on the occurrence of ventricular fibrillation, identifying strategies for treatment or prevention of ventricular fibrillation or ventricular tachycardia, and evaluating a subject for induction of ventricular fibrillation from a condition of ventricular tachycardia. | 2010-09-16 |
20100233089 | IMAGING OF GENETIC MATERIAL WITH MAGNETIC RESONANCE - A method for imaging genetic material such as DNA, RNA and genes by magnetic resonance imaging incorporating hyperpolarization techniques, such as PASADENA or DNP may be used in various app metabolomics, medical diagnosis and genetic research. | 2010-09-16 |
20100233090 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES - Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA. | 2010-09-16 |
20100233091 | Pyrazine Derivatives with Extended Conjugation and Methods of Using the same in Optical Applications - The present invention relates to pyrazine derivatives capable of absorbing and emanating spectral energy in the visible and/or near infrared spectrum. Pyrazine derivatives of the invention may be administered to a patient in the form of a pharmaceutically acceptable composition and utilized in medical (e.g., diagnostic imaging) procedures. | 2010-09-16 |
20100233092 | IN-VIVO MONITORING OF CIRCULATING APOPTOTIC CELLS - The present invention provides methods and systems for performing in vivo flow cytometry. In one embodiments, selected circulating cells of interest of a subject are labeled with fluorescent probe molecules. The labeled cells are irradiated in-vivo so as to excite the fluorescent probes, and the radiation emitted by the excited probes is detected, preferably confocally. The detected radiation is then analyzed to derive desired information, such as relative cell count, of the cells of interest. In some embodiments, the circulating cells comprise apoptotic cells whose detection can allow, e.g., non-invasive monitoring of the efficacy of a cancer treatment, such as an anti-tumor or an anti-angiogenic therapy. | 2010-09-16 |
20100233093 | Magnetic resonance imaging contrast agent with paramagnetic-inositol phosphates complexes - Disclosed are novel MRI contrast agents and imaging methods using the same. The novel MRI contrast agent comprises a chelating molecule with at least two phosphate groups coordinated with at least one paramagnetic substances. | 2010-09-16 |
20100233094 | PERFLUOROCARBON NANO-EMULSION CONTAINING QUANTUM DOT NANOPARTICLES AND METHOD FOR PREPARING THE SAME - The present invention relates to a perfluorocarbon nanoemulsion containing quantum dot nanoparticles and a method for preparing the same, more specifically, relates to a method for preparing a multifunctional perfluorocarbon nanoemulsion which simultaneously shows the fluorine-based magnetic resonance properties of perfluorocarbon and the optical properties of quantum dot nanoparticles, the method comprising dispersing quantum dot nanoparticles, modified with a fluorine end group, in perfluorocarbon, and then adding an aqueous emulsifier solution containing lipid to the dispersion. The disclosed perfluorocarbon nanoemulsion containing quantum dot nanoparticles has excellent biocompatibility and simultaneously shows optical properties and magnetic resonance properties, and thus can be used as a contrast agent for multi-mode molecular imaging. Accordingly, the nanoemulsion can be used to study cell and small-animal molecular imaging in various fields, including biological and medical fields. | 2010-09-16 |
20100233095 | CONFORMATIONALLY DYNAMIC PEPTIDES - Disclosed are novel peptides that are useful, for example, for detecting target proteins having a β-sheet secondary structure which may be associated with a disease, and for diagnosing and treating such a disease. Related methods and kits also are disclosed. | 2010-09-16 |
20100233096 | METHOD TO PRODUCE HYPERPOLARISED CARBOXYLATES AND SULPHONATES - The invention relates to a dynamic nuclear polarisation method for producing hyperpolarised carboxylates or sulphonates or mixtures thereof wherein the carboxylate or sulphonate used in the method of the invention comprises certain inorganic cations. The invention further relates to compositions for use in that method. | 2010-09-16 |
20100233097 | CONTRAST AGENTS - Compounds of formula (I) R | 2010-09-16 |
20100233098 | Method and Composition for Disinfecting Hard Surfaces - Aqueous hard surface treatment compositions necessarily comprise an alcohol constituent selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, n-butanol, benzyl alcohol, and mixtures thereof which alcohol constituent comprises from about 40 and 70 weight percent (“% wt”) of the total weight of the composition of which it forms a part. Preferably however the alcohol constituent is present in an amount of from about 50% wt to about 70% wt, more preferably is present in amounts of from about 60% wt to about 70% wt. | 2010-09-16 |
20100233099 | DEVICE FOR INTRANASAL ADMINISTRATION - Disclosed herein are devices and processes for preparing a vial for an intranasal administration of a medicament where the vial comprises reduced oxygen content. | 2010-09-16 |
20100233100 | AMPHIPHILIC COPOLYMERIC MATERIAL - An amphiphilic polymeric material which has a straight or branched chain polymer backbone and a multiplicity of side chains attached to the backbone, wherein the backbone is a copolymer of at least one ethylenically-unsaturated aliphatic hydrocarbon monomer and maleic anhydride, or is a terpolymer of maleic anhydride, ethylene, and a further ethylenically unsaturated monomer. A method of synthesising said polymeric material is also provided, together with chewing gum bases, compositions and emulsions comprising amphiphilic polymeric materials. | 2010-09-16 |
20100233101 | Composition and method for the oxidative consumption of salivary biomolecules - The composition and method for the use of stabilized chlorine dioxide as an antimicrobial agent against oral microorganisms for the treatment and prevention of halitosis and prevention of oral diseases through its oxidative consumption and inactivation of volatile sulfur compounds and their amino acid precursors is disclosed. Preferred concentrations of stabilized chlorine dioxide in this invention are in the range of 0.005% to 2.0% (w/v). | 2010-09-16 |
20100233102 | USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS - The invention provides the use of
| 2010-09-16 |
20100233103 | Water-In-Oil Type Emulsion Sunscreen Cosmetics - The present invention provides water-in-oil type emulsion sunscreen cosmetics that achieve an excellent UV blocking effect, and have excellent effects in the prevention and inhibition of discoloration (discoloration to red). The water-in-oil emulsion sunscreen cosmetic according to the present invention is characterized by comprising: (a) octocrylene; (b) hydrophobized zinc oxide; (c) cationic surfactant; and (d) silica. | 2010-09-16 |
20100233104 | Amino-Acid Functional Siloxanes, Methods Of Preparation and Applications - A method of preparing an amino acid functional siloxane by reacting an amino acid derivative selected from the group of an N-acyl amino acid and an N-aroyl amino acid with an amino functional siloxane optionally in the presence of a solvent. The invention extends to personal care products containing the resulting amino acid functional siloxanes. | 2010-09-16 |
20100233105 | Composite spherical polymer particles and their production process, and cosmetics using the same - Composite spherical polymer particles contain a nanoparticulate pigment having an average primary particle size of from 0.1 to 0.005 μm, a high molecular dispersant having adsorptive property to the nanoparticulate pigment, and a (meth)acrylic resin. The nanoparticulate pigment is enclosed in a dispersed state in the high molecular dispersant and (meth)acrylic resin. The content of the nanoparticulate pigment ranges from 5 to 70 wt % based on the composite spherical polymer particles. The composite spherical polymer particles have an average particle size of from 1 to 20 μm. A production process of the composite spherical polymer particles and cosmetics containing the composite spherical polymer particles are also disclosed. | 2010-09-16 |
20100233106 | SMALL-MOLECULE MODULATORS OF MELANIN EXPRESSION - The present invention relates to small molecule modulators of melanin expression and methods of making the small molecules. Also disclosed are methods of increasing pigmentation in a cell which involve providing compounds of the present invention and contacting a cell with the compounds under conditions effective to induce melanin expression in the cell, thereby increasing pigmentation. The present invention also relates to compositions containing compounds of the present invention and a carrier. | 2010-09-16 |
20100233107 | MEDICATED TONING LOTION - A skin lotion includes, as a principal ingredient, a crosspolymer compound with as much as 50% adsorbed Salicylic Acid which can be gradually released to the skin after application. The lotion can also include, surfactants, humectants, preservatives, moisturizers, sunblocks, antibacterials and retinol precursors. A hydrophobically modified polymer contributes a smooth feel to the lotion. | 2010-09-16 |
20100233108 | PROCESS FOR THE PREPARATION OF INVERSE LATEX OF ACRYLAMIDE-BASED POLYMERS AND COMPOSITION COMPRISING SAID LATEX - Process for the preparation of a composition including an oil phase, an aqueous phase, at least one emulsifying system of water-in-oil (W/O) type, optionally at least one emulsifying system of oil-in-water (O/W) type, in the form of an inverse latex including from 20% to 70% by weight and preferably from 25% to 50% by weight of a branched or crosslinked polyelectrolyte, characterized in that the polyelectrolyte is a copolymer of 2-acrylamido-2-methylpropanesulfonic acid partially or totally salified with acrylamide and optionally one or more monomers chosen from monomers containing a partially or totally salified weak acid function and/or from neutral monomers other than acrylamide, the production process being characterized in that the preparation of the aqueous phase includes the dissolution in the aqueous medium of solid 2-acrylamido-2-methyl propanesulfonic acid before neutralization. Cosmetic, dermopharmaceutical or pharmaceutical composition including the inverse latex directly obtained by the process. | 2010-09-16 |
20100233109 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS - The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using α | 2010-09-16 |
20100233110 | Powder Compositions Containing Edible Grains - A powder composition comprising a particulate phase containing a plurality of edible grains. | 2010-09-16 |
20100233111 | GASTROPOD BIOLOGICAL FLUID, METHOD OF MAKING AND REFINING AND USE - The present technology generally relates to skin care compositions, cosmeceuticals or formulations and methods of making or using the same. More specifically, the presently described technology generally relates to methods of making and using compositions, cosmeceuticals or formulations including a unique composition collected and refine from a gastropod, namely | 2010-09-16 |
20100233112 | SHAPE MEMORY POLYMER NETWORK USING HETEROCYCLIC GROUPS - A shape memory polymer network may include at least one polymer, a plurality of proton accepting heterocyclic groups, a plurality of proton donating groups, and a plurality of cross-link moieties. At least one of the proton accepting heterocyclic groups and the proton donating groups is attached to the at least one polymer. The network may include an original shape at zero stress, and may include a deformed shape upon subjection to a stress. The network changes from the deformed shape to the original shape upon exposure to an external stimulus. | 2010-09-16 |
20100233113 | PROCESS FOR INHIBITING DYED HAIR FIBERS FROM LOSING THEIR COLOR DURING SHAMPOOING - A process for inhibiting dyed hair fibers from losing their color during shampooing involving contacting the dyed hair fibers with a composition containing: (a) at least one polyamine compound having at least two amino groups; (b) at least one anionic silicone; and (c) optionally, at least one surfactant, and wherein (a) is present in the composition in an amount sufficient to inhibit the dyed hair fibers from losing their color during shampooing. | 2010-09-16 |
20100233114 | METHODS OF STYLING HAIR - The invention relates to compositions containing at least one silicone film forming resin and at least one polysilicone polymer, as well as to methods of applying such compositions to keratin materials. | 2010-09-16 |
20100233115 | Multilayer Fibrous Polymer Scaffolds, Methods of Production and Methods of Use - Fibrous polymer scaffolds and methods of manufacture are provided. The scaffolds can be formed of multiple layers and the extent and direction of alignment of each layer can be controlled. Efficient fabrication systems and methods for producing such scaffolds include apparatuses and processes are also provided. Kits including the fibrous polymer scaffolds and methods for implanting such scaffolds are also provided. | 2010-09-16 |
20100233116 | ORGANIC COMPOUNDS - The present invention provides heterocyclic derivatives hat modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 2010-09-16 |
20100233117 | Adjuvant combination formulations - The use of 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A and derivatives and analogs thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12 is useful as an adjuvant combination in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen. | 2010-09-16 |
20100233118 | USE OF WF10 FOR TREATING ALLERGIC ASTHMA, ALLERGIC RHINITIS AND ATOPIC DERMATITIS - The present invention provides a method of inhibiting at least one of allergic asthma, allergic rhinitis and atopic. The present invention further provides a method for the reduction, prevention or treatment of allergy like symptoms in a subject. | 2010-09-16 |
20100233119 | SUPPRESSION OF IMMUNE RESPONSE TO FACTOR VIII IN HEMOPHILIA A PATIENTS - This invention relates to methods and compositions for suppressing an immune response to Factor VIII in subjects suffering from hemophilia A and having preformed inhibitor antibodies against Factor VIII, and compositions and methods that advantageously render subjects amenable to standard treatments for hemophilia A, including Factor VIII replacement therapy. | 2010-09-16 |
20100233120 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2010-09-16 |
20100233121 | METHOD FOR TREATING MULTIPLE SCLEROSIS - Methods for treating multiple sclerosis (MS) with a CD20 antibody using special dosing regimens and protocols are described. Articles of manufacture for use in such methods are also described. | 2010-09-16 |
20100233122 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2010-09-16 |
20100233123 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS - Provided herein are phosphothiophene and phosphothiazole compounds, for example, of any of Formulae I, IA, IIA, IIIA, IVA, VA, VIA, VIIA, IB, IIB, IIIB, IVB, VB, VIIB and VIIB disclosed herein, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host infected with HCV. | 2010-09-16 |
20100233124 | BACILLUS BASED DELIVERY SYSTEM AND METHODS OF USE | 2010-09-16 |
20100233125 | CHIMERIC ADENOVIRUS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL USING THE SAME - The invention relates to novel chimeric adenoviruses comprising the type 5-modified chimeric adenoviruses, in which the fiber knob domain in the adenoviruses type 5 is replaced by the adenoviruses type 35 fiber knob domain and any exogenous transcriptional regulatory regions controlling expression of the E1A and E1B genes are introduced into the region from which adenoviruses type 5 E1A transcriptional regulatory region has been removed. The chimeric adenoviruses are cytotoxic or oncolytic chimeric adenoviruses and can be utilized as, for example, pharmaceutical agents having high cytotoxic activity against intractable tumors such as malignant mesothelioma. | 2010-09-16 |
20100233126 | POLYPEPTIDE - The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours. | 2010-09-16 |
20100233127 | TARGETED VECTORS FOR CANCER IMMUNOTHERAPY - This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject. Also provided are a kit or drug delivery system comprising the compositions for use in the methods described. | 2010-09-16 |
20100233128 | Natural Skin Products Containing Dairy and Processes - A skincare product containing one or more dairy products, and one or more ingredients such as a natural oil, an herb, a fruit, a vegetable, a grain, honey, sea salt, egg yolk and mixtures thereof, for application to human skin in order to improve the well-being of said skin. The skincare product is applied to the skin in order to cleanse, beautify, promote attractiveness, and/or alter the feel or appearance of the skin. Furthermore, the skincare product is applied to the skin by rubbing, pouring, sprinkling, and/or spraying the skincare product onto the skin. | 2010-09-16 |
20100233129 | PREVENTION AND TREATMENT OF SECONDARY INFECTIONS FOLLOWING VIRAL INFECTION - This invention relates to a synthetic nutritional composition suitable for use in the prevention of secondary infections following a viral infection characterised by neuraminidase activity comprising a sialylated oligosaccharide and N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine The invention further extends to the use of such a composition in the prevention of secondary infections such as otitis media. | 2010-09-16 |
20100233130 | Method and Apparatus for Maintenance and Expansion of Hematopoietic Stem Cells From Mononuclear Cells - A method of expanding/maintaining undifferentiated hematopoietic stem cells by obtaining unselected mononuclear cells; and seeding the mononuclear cells into a stationary phase plug-flow bioreactor in which a three dimensional mesenchymal/stromal cell culture has been pre-established, thereby expanding/maintaining undifferentiated hematopoietic stem cells. | 2010-09-16 |
20100233131 | SELENIUM DEDIFFERENTIATED CELL, PREPARATION METHOD AND USAGE THEREOF - Provided are a cell therapeutic composition containing selenium, a method of dedifferentiating selenium-treated cells, a cell therapeutic composition containing cells dedifferentiated from the selenium-treated cells by the same method, and a cell therapeutic composition containing cells redifferentiated from the dedifferentiated cells. | 2010-09-16 |
20100233132 | FORMATION OF VASCULAR NETWORKS USING EMBRYONIC STEM CELLS - In various aspects, provided are methods for providing CD34 | 2010-09-16 |
20100233133 | TISSUE REPAIR - According to the invention there is provided a cosmetic method for the augmentation of subcutaneous or dermal tissue in a subject, which method comprises the steps of: (i) providing a suspension of autologous dermal fibroblasts; and (ii) injecting an effective volume of the suspension into tissue subadjacent to the subcutaneous or dermal tissue so that the tissue is augmented; wherein the fibroblasts are suspended in HypoThermosol®, preferably HypoThermosol® FRS. | 2010-09-16 |
20100233134 | Use of Adipose-Tissue Cell Fractions for Post-Irradiation Tissue Regeneration - The present invention concerns the use of cells derived from the cellular fraction of the vascular stroma of the extramedullary adipose tissue to promote the regeneration of tissue following lesions caused by irradiation. More specifically, the use according to the invention aims to prepare a drug for promoting regeneration of the skin, and in particular to repair the cutaneous wounds caused by irradiation. | 2010-09-16 |
20100233135 | COMPOSITIONS AND METHODS FOR HEMATOPOIETIC STEM CELL EXPANSION OR FOR MODULATING ANGIOGENESIS - The present invention provides compositions and methods featuring ZBP-89 polypeptides or nucleic acid molecules for expanding a hematopoietic stem cell population or for modulating angiogenesis. | 2010-09-16 |
20100233136 | ISOLATED POPULATIONS OF CELLS AND METHODS OF GENERATING AND USING SAME - An isolated homogeneous population of cells comprising a plurality of human ectodermal progenitor cells. Also provided are methods of generating and using the population of cells. | 2010-09-16 |
20100233137 | Compositions and Methods for Modification of Target Cells and to Their Uses Thereof - Methods and compositions are described for preparing modified cells useful in various therapeutic applications. | 2010-09-16 |
20100233138 | Vocal Cord Augmentation Utilizing Muscle-Derived Progenitor Compositions, and Treatments Thereof - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment vocal cord tissue following introduction (e.g. via injection, transplantation, or implantation) into the vocal cords. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, vocal cords in the treatment of various cosmetic or functional conditions, including vocal cord tissue weakness, voice and swallowing disorders. The invention also relates to the novel use of MDCs for the increase of vocal cord tissue mass in speakers, singers or other people in need of greater than average vocal cord tissue mass. | 2010-09-16 |
20100233139 | METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER - Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed. | 2010-09-16 |
20100233140 | COLLAGEN-CONTAINING CELL CARRIER - The present invention relates to the use of a collagen-containing composition for the cultivation of biological cells, a method for the cultivation of biological cells, a method for the implantation of biological material into an organism and a method for the improvement of a composition in its suitability for the cultivation of biological cells. | 2010-09-16 |
20100233141 | Compositions And Methods For The Delivery Of Biologically Active RNAs - The present invention provides novel compounds, compositions, and methods for the delivery of biologically active RNA molecules to cells. Specifically, the invention provides novel nucleic acid molecules, polypeptides, and RNA-protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition, the invention provides cells and compositions comprising the novel compounds and vectors, which can be used as transfection reagents. The invention further provides methods for producing said compounds, vectors, cells, and compositions. Additionally, vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided. The novel compounds, vectors, cells, and compositions are useful, for example, in delivering biologically active RNA molecules to cells to modulate target gene expression in the diagnosis, prevention, amelioration, and/or treatment of diseases, disorders, or conditions in a subject or organism. | 2010-09-16 |
20100233142 | Stem Cells Derived from Uniparental Embryos and Methods of Use Thereof - Embryonic stem cells derived from uniparental embryos and methods of use thereof are disclosed. | 2010-09-16 |
20100233143 | Parthenogenic Activation of Human Oocytes for the Production of Human Embryonic Stem Cells - Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O | 2010-09-16 |
20100233144 | METHOD FOR OPTIMIZING BLOOD CELL TRANSPLANTS - The invention relates to the use of allogenic T lymphocytes for the preparation of a composition intended to be injected into a recipient patient as a conditioning for a transplantation of haematopoietic stem cells, said allogenic T lymphocytes expressing a molecule allowing their specific destruction. | 2010-09-16 |
20100233145 | COMPOSITION USED AS A NUTRITIONAL SUPPLEMENT AND MEDICATION FOR THE TREATMENT OF DEGENERATIVE VISUAL DISORDERS AND INFLAMMATION - A composition and a dosing unit which can be used as nutritional supplement or as medication for the treatment of retinitis pigmentosa (RP). The composition comprises a combination of lutein, zeaxanthin, glutathione and alpha lipoic acid, optionally supplemented with an extract of Lucium Barbarum Lynn. This composition inhibits the death of photoreceptors as a consequence of RP, whereby the visual faculties of the patient are retained for a longer time. The composition is also useful as an anti-inflammatory drug. | 2010-09-16 |
20100233146 | Coatings and Surface Treatments Having Active Enzymes and Peptides - Disclosed herein are a materials such as a coating, an elastomer, an adhesive, a sealant, a textile finish, a wax, and a filler for such a material, wherein the material includes an enzyme such as an esterase (e.g., a lipolytic enzyme, a sulfuric ester hydrolase, an organophosphorus compound degradation enzyme), an enzyme that degrades a cell wall and/or a cell membrane component (e.g., a lysozyme, a lytic transgrycosylase, a peptidase), and/or a biocidal or biostatic peptide. Also disclosed herein are methods of decontaminating a surface comprising such a material from a chemical substrate of an enzyme such as a lipid or an organophosphorus compound, as well as reducing the growth of a microorganism on or within such a material. | 2010-09-16 |
20100233147 | METHOD AND APPARATUS FOR THROMBUS REMOVAL USING MAGNETIC PARTICLES - A method and system for affecting a thrombus after ischemic stroke. The method may include injecting a plurality of magnetic particles into a bloodstream and moving or distorting a thrombus formed or lodged in the bloodstream using a magnetic force to manipulate the magnetic particles. The method may include conjugating ferromagnetic particles, paramagnetic particles, or superparamagnetic particles to a thrombus-specific attachment agent such as an anti-fibrin antibody, and injecting the conjugated particles into the bloodstream. Thereafter, the thrombus may be agitated, broken apart, or dissolved using a magnetic field to exert a magnetic force on the conjugated particles. The method may also include injecting a thrombolytic agent into the bloodstream to interact with and further dissolve the thrombus. | 2010-09-16 |
20100233148 | Injection of fibrin sealant including an anesthetic in spinal applications - A method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus. The method includes injecting a fibrin sealant into the disc to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises an anesthetic, fibrinogen and an activating compound, wherein at least a portion of the fibrin forms after injection, with the proviso that a corticosteroid is absent from the fibrin sealant injected into the disc. | 2010-09-16 |
20100233149 | Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same - Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, compositions comprising Factor X and Factor Xa, inactivated Factor X and inactivated Factor Xa and methods of medical treatment using Factor X, Factor Xa, activated Factor X and inactivated Factor Xa are disclosed. The preparation methods comprise a chromatography step using an immobilised metal ion affinity chromatography substrate. | 2010-09-16 |
20100233150 | REDUCTION OF ADIPOSE TISSUE - The amount of adipose tissue, including lipomas, at selected locations in the body is reduced by introducing collagenase or collagenase plus another proteinase into the tissue. | 2010-09-16 |
20100233151 | COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 2010-09-16 |
20100233152 | Use of HMGB proteins and nucleic acids that code therefor - The invention relates to the use of HMGB and/or a nucleic acid that codes therefor and/or an interaction partner of HMGB that is in particular natural and/or a nucleic acid that codes therefor as a target molecule for the development and/or production of a medicament for the treatment and/or prevention of diseases of the endometrium and/or for the development and/or production of a diagnostic agent for diagnosing diseases of the endometrium. | 2010-09-16 |
20100233153 | NOVEL GENE DISRUPTIONS, COMPOSITIONS AND THE METHODS RELATING THERETO - The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO1105, PRO1279 or PRO1783 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities. | 2010-09-16 |
20100233154 | TARGETED BINDING AGENTS DIRECTED TO HEPARANASE AND USES THEREOF 463 - The invention relates to targeted binding agents that specifically bind to heparanase and inhibit the biological activity of heparanase and uses of such agents. More specifically the invention relates to fully human monoclonal antibodies directed to that specifically bind to heparanase and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The disclosed targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of heparanase. | 2010-09-16 |
20100233155 | HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR - The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods. | 2010-09-16 |
20100233156 | Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors - Provided herein are methods of treating an acute central nervous system injury in a subject. The methods comprise administering to the subject a γ or β secretase inhibitor, an Aβ antibody, or an immunogenic fragment of Aβ. | 2010-09-16 |
20100233157 | HUMAN ANTIBODIES AGAINST HUMAN FAS AND THEIR USE - Binding members directed to human Fas (Fas), in particular antibody molecules against human Fas, employing the antibody VH and/or VL domain of the antibody molecule termed F45D9, which may be in IgG1 or IgG4 format. Methods of use in patients, diseases or disorders involving apoptosis, such as Graft-Versus-Host Disease, HIV-infection, Stevens-Johnson syndrome or Toxic epidermal necrolysis, Islet transplantation as treatment for insulin-dependent diabetes, diseases based on ischemia or ischemic reperfusion injury, heart disease, renal disease, neurological disorders and injuries and lymphocyte depletion in cancer patients associated to cytotoxic antineoplastic therapy. | 2010-09-16 |
20100233158 | INDUCTION OF IMMUNE TOLERANCE - Methods of inducing immune tolerance by administering an immunosuppressive agent and a compound represented by Formula (I) are disclosed: | 2010-09-16 |
20100233159 | METHODS OF TREATING STROKE - Methods and compositions for treating stroke are disclosed. | 2010-09-16 |
20100233160 | Monoclonal Anti-Annexin A3 Antibodies for the Detection of Prostate Carcinoma - The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3, particularly of extracellular annexin A3 with highly specific antibodies, particularly with monoclonal antibodies. The present invention further refers to a test reagent comprising such antibodies. | 2010-09-16 |
20100233161 | NOVEL MULTIFUNCTIONAL COMPOUNDS FOR PHARMACEUTICAL PURPOSES - The invention relates to a synthetic bifunctional non-antibody compound comprising one or more effector moieties and one or more binder moieties, wherein the effector moieties are operably linked to the binder moieties via a linker, the effector moieties are ligands to at least one pathogen pattern recognition receptor (PRR) and the binder moieties bind to a marker of a tumor cell. | 2010-09-16 |
20100233162 | LOCAL ADMINISTRATION OF CHICKEN YOLK IMMUNE GLOBULINS (IgY) TO TREAT AND PREVENT FUNGAL INFECTIONS - The present invention relates to a composition comprising IgY antibodies against at least two different fungi, the use of the composition for the preparation of a pharmaceutical especially for prophylaxis and/or therapy of all kinds of fungal infections, such as conditions caused by organisms belonging to the | 2010-09-16 |
20100233164 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES - Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2010-09-16 |
20100233165 | INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGETING PROSTATE CANCER CELLS IN SITU - This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens. | 2010-09-16 |
20100233166 | NOVEL IDO INHIBITORS AND METHODS OF USE - Compounds, compositions and methods for the treatment of malignancy are disclosed. | 2010-09-16 |
20100233167 | CHAIN REACTION CREATING OLIGOMERS FROM REPEAT UNITS OF BINDING MOLECULES - The present invention concerns a chain reaction of cross-linking antibodies or other binding molecules prior or subsequent to binding to a target, such as a target antigen. The invention further concerns oligomers comprising repeat units of binding molecules, such as antibodies, optionally bound to a target, such as a target antigen. The invention also relates to antibodies and other binding molecules with multiple specificities useful in the methods of the invention, as well as various uses of the oligomers and individual binding molecules present in the oligomers. | 2010-09-16 |
20100233168 | Rationale for IL-1 Beta targeted therapy in sickle cell disease for ischemia-reperfusion induced complications - Sickle cell patients atypically experience exaggerated inflammatory responses to pathogens that normally cause mild respiratory infections in non-sickle cell humans. There appears to be heightened inflammatory responses to pathogens in combination with hypoxia in sickle cell disease. The novelty of this invention provides a new paradigm to explain the exaggerated inflammatory response of sickle cell disease to pathogens especially when accompanied by hypoxic stress. In particular, sickle cell chest injury and other complications associated with ischemia-reperfusion injury caused by vaso-occlusion can involve co-stimulation of the NALP-3 inflammasome by pathogen associated molecular patterns (PAMPs) and hypoxic-induced danger associated molecular patterns (DAMPs), leading to exaggerated pro-inflammatory responses marked by increased IL-1β secretion and subsequent induction of neutrophilic inflammation. This invention thereby provides the immunologic, biologic and biochemical rationale for IL-1β targeted therapies in sickle cell disease to block the pathological effects of IL-1β that leads to exaggerated inflammatory expressions, including neutrophilic inflammation. | 2010-09-16 |
20100233169 | Methods for treating obesity using fibroblast growth factor-Like polypeptides - The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides. | 2010-09-16 |
20100233170 | Fully human antibodies against N-Cadherin - The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer. | 2010-09-16 |
20100233171 | Differential Drug Sensitivity - We describe a method to diagnose and treat an animal, preferably a human, suffering from a condition, typically cancer, that would benefit from a stimulation of apoptosis in tumour cells and including screening methods to identify new chemotherapeutic agents. | 2010-09-16 |
20100233172 | METHODS OF INHIBITING QUIESCENT TUMOR PROLIFERATION - Improved compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders, and methods of screening to identify compounds for such treatments. | 2010-09-16 |